CAS 1059070-10-8

6-Amino-2-(butylamino)-9-[[6-[2-(dimethylamino)ethoxy]-3-pyridinyl]methyl]-7,9-dihydro-8H-purin-8-one

CAS: 1059070-10-8

Formel: C₁₉H₂₈N₈O₂

Reinheit: 99%

Farbe und Form: Solid

Molekulargewicht: 400.4780

Ref: IN-DA01ENNM

6-Amino-2-(Butylamino)-9-((6-(2-(Dimethylamino)Ethoxy)Pyridin-3-Yl)Methyl)-7,9-Dihydro-8H-Purin-8-One

CAS: 1059070-10-8

6-Amino-2-(Butylamino)-9-((6-(2-(Dimethylamino)Ethoxy)Pyridin-3-Yl)Methyl)-7,9-Dihydro-8H-Purin-8-One

Reinheit: 98%

Molekulargewicht: 400.48g/mol

Ref: 54-OR1023127

6-Amino-2-(butylamino)-9-[[6-[2-(dimethylamino)ethoxy]-3-pyridinyl]methyl]-7,9-dihydro-8H-purin-8-one

CAS: 1059070-10-8

Reinheit: 99%

Molekulargewicht: 400.4869995

Ref: 10-F866879

DSR 6434

Kontrolliertes Produkt

CAS: 1059070-10-8

Formel: C₁₉H₂₈N₈O₂

Farbe und Form: Neat

Molekulargewicht: 400.478

Ref: TR-C982610

DSR-6434

Kontrolliertes Produkt

CAS: 1059070-10-8

DSR-6434 is a Toll-like receptor modulator that is used in the treatment of human immunodeficiency virus. It has been shown to inhibit the production of cytokines and chemokines, which are necessary for viral replication. This molecule also has the potential to be used as a therapeutic agent in autoimmune diseases, hepatitis, and renal cell cancer. DSR-6434 is a small molecule drug that binds to Toll-like receptor 4 (TLR4). The compound blocks TLR4 signaling through a neutralizing mechanism by binding to TLR4 on the surface of cells, preventing it from activating downstream signaling pathways. DSR-6434 has been shown to have clinical activity against colorectal carcinoma in preclinical studies.

Formel: C₁₉H₂₈N₈O₂

Reinheit: Min. 95%

Molekulargewicht: 400.48 g/mol

Ref: 3D-JSB07010

DSR-6434

CAS: 1059070-10-8

DSR-6434 is a selective agonist of TLR7 with antitumor effect. DSR-6434 exhibits EC50s of 7.2 nM and 4.6 nM for human and mouse.

Formel: C₁₉H₂₈N₈O₂

Reinheit: 99.78%

Farbe und Form: Solid

Molekulargewicht: 400.48

Ref: TM-T11108